Philip Morris International Launches New IQOS ILUMA in Guatemala

Business by 2FIRSTS.ai
Nov.27.2023
Philip Morris International Launches New IQOS ILUMA in Guatemala
Philip Morris International (PMI) subsidiary, TACASA, launches new heated tobacco product IQOS ILUMA in Guatemala, offering three different models.

Recently, according to news from Newsinamerica, Philip Morris International (PMI) has launched its latest heated tobacco product IQOS ILUMA in Guatemala through its subsidiary Central American Tobacco Company (TACASA).

 

The new IQOS ILUMA range consists of three models: IQOS ILUMA PRIME, IQOS ILUMA ONE, and IQOS ILUMA. All three devices feature the Smartcore sensing system but offer different designs to cater to the varying needs of adult users. They also offer high-quality accessories to enhance the user experience.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Six Years of Data Show FDA Clearing PMTA Backlog
Six Years of Data Show FDA Clearing PMTA Backlog
FDA data from FY2020 to FY2025 show how the PMTA system for e-cigarette products evolved after an early surge of submissions created prolonged front-end delays. Millions of applications accumulated at the Acceptance stage before entering substantive review. Since 2023, the number of applications pending acceptance has declined sharply, and industry participants report shorter initial decision timelines in late 2025.
Feb.06
China to Cancel VAT Export Rebates on E-Cigarette Products from April 1, 2026
China to Cancel VAT Export Rebates on E-Cigarette Products from April 1, 2026
China’s Ministry of Finance and State Taxation Administration have announced adjustments to export tax rebate policies, placing nicotine-containing non-combustible inhalation products within the scope of items subject to rebate cancellation. The measures will take effect from April 1, 2026.
Regulations
Jan.10
JTI UK Updates Nordic Spirit Packaging to Strengthen “Strength and Flavour” Guidance
JTI UK Updates Nordic Spirit Packaging to Strengthen “Strength and Flavour” Guidance
Japan Tobacco International UK (JTI UK) has unveiled a refreshed brand identity for Nordic Spirit nicotine pouches. The new packaging is now live on JTI360 and will roll out to shelves over the coming months. The updated design strengthens on-pack guidance on strength and flavour, adding slower/faster release cues and a six-dot strength system (6–17mg). Each can contains 20 pouches and includes a lid compartment for storing used pouches before disposal.
Mar.04 by 2FIRSTS.ai
Japan Tobacco International Malaysia Appoints Didier Ellena as Managing Director; Predecessor Reassigned to North Asia Role
Japan Tobacco International Malaysia Appoints Didier Ellena as Managing Director; Predecessor Reassigned to North Asia Role
Japan Tobacco International (JTI) Malaysia has appointed Didier Ellena as managing director, effective Jan 5. Ellena has spent more than 30 years with JTI and has held leadership roles across multiple countries and regions. His predecessor, Juliana Mohd Yahaya, will become vice president of sales and marketing for JTI North Asia.
Jan.15 by 2FIRSTS.ai
Daegu Jung-gu: liquid e-cigarettes with synthetic nicotine to be fined in nonsmoking areas under revised Tobacco Business Act
Daegu Jung-gu: liquid e-cigarettes with synthetic nicotine to be fined in nonsmoking areas under revised Tobacco Business Act
Daegu’s Jung-gu District announced on Feb. 10 that, following amendments to the Tobacco Business Act that explicitly classify liquid e-cigarettes containing synthetic nicotine as “tobacco” (effective April 24, 2026), the district will expand regulations to include fines for vaping such products in designated nonsmoking areas. The district health office said smokers/vapers could face an administrative fine of up to 100,000 won for using synthetic-nicotine liquid e-cigarettes in smoke-free zones
Feb.10 by 2FIRSTS.ai
PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries
PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries
At the opening of FDA’s PMTA roundtable, small ENDS manufacturers warned that unclear product characterization standards are limiting their ability to invest and raise capital. FDA officials acknowledged industry concerns but said regulatory flexibility is constrained by statutory and procedural boundaries.
Feb.11